• Aliases: AZD6244, ARRY-142886
    • An orally bioavailable small molecule that inhibits MEK or MAPK/ERK kinases 1 and 2
    • Currently under investigation in phase 2 clinical trials for Kaposi sarcoma, melanoma, metastatic pancreatic cancer, colorectal cancer, NSCLC, and large B-cell lymphoma
    • Recommended dose: 50 to 75 mg PO twice daily
    • Half-life: 8.3 hours
    • Common side effects: Nausea/vomiting, acneiform dermatitis, diarrhea, peripheral edema
    (Adjei et al., 2008)
    Other topics in Targeted and Immunotherapy Agents